~eproductiGe ~iblogy, section 4052, Rigshospitalet, Copenhagen, Denmark FERTILITY AND SEMEN QUALITY IN PREVIOUSLY GROWTH HORMONE TREATED MEN. 32 men aged 20-35 years (median 27.3 years) who were treated in childhood or adolescence with growth hormone participated in the study. Sixteen had isolated growth hormone deficiency and 16 panhypopituitarism with insufficiency of two oy more pituitary hormones including growth hormone. All patients were adequately hormone substituted except growth hormone. They were all interviewed. Only one patient, a man aged 27 with partial growth hormone deficiency, had fathered a child. Seven of ten patients with 'complete growth hormone deficiency' (<3.0 ng/ml) were asked to deliver seminal fluid by masturbation. None had normal spermiograms. Four patients with panhypopituitarism had very low volume of seminal fluid ( < 1 ml) and azoospermia, whereas three patients with isolated growth hormone deficiency showed moderate impairment of the spermiogram including abnormal motility. Thus, the majority of men with growth hormone deficiency may have dysfunction of the reproductive system. with insulin hypoglycaemia and growth hormone peak concentrations <7 ng/ml, were reevaluated with clonidine stimulation test. Twelve of 13 patients with panhypopituitarism still showed severe growth hormone aeficiency (<5 ng/ml peak concentration). Of the 23 isolated growth hormone deficient persons only 11 still showed severe growth hormone deficiency while 4 persons showed signs of partial growth hormone deficiency (5.4-8.6 ng/ml). Eight persons had normal growth hormone response. In conclusion: 1) In children with panhypopituitarism the growth hormone deficiency may be more definite than in children with an isolated defect, or alterna-A stlmulatory test with intravenous GHRH (2mcg/kg) and study of physiological GH secretion over the 24-hour period 1~11th GH sampllng every 20 min (calculation of the Integrated concentration (IC) and the value of the maxlmum nocturnal peak) was carried out in 94 children. Thelr mean age was 10.75Z3.35~r and mean growth retardatlon -2.7810.67 SD. The means of the parameters studied were : GH peak after GHRIl 30.4~16.8~ng/ml, IC 3.11Z1.97ng/ml/m1n and physlologlcal secretory peak 26-4ng/ml. The children were divlded Into three subgroups according to their IC : normal IC (~l ,m=4;67+2.2ng/ ml/min,n=39), intermediate (G2 ,m=2.36Z0.3ng/ml/min, n=30) and low (~3,m=1.65+0.45ng/lnl/min, n=25). The mean of GH peaks after GllRll did not signlticantly differ between the three subgroups. The means were respectively : G1,32.97?2.71 ng/ml; ~2,30.39:2.9 ng/ml; and ~3,26.25+3.61 ng/ml. There was no significant correlation between the GH peak after GHHII on the one hand and the IC or the physiological secretory peak on the other In these three groups. The GHRH test was considered posltive when the Gli peak was greater than 10 ng/ml. 77 of 94 children had a positive response. 17 ch~ldren d~d not respond to GIIRII stimulation. Study of the physiological secretlon showed GI1 deficiency in 6 of the 17 children (mean IC 1.45: 0.20), but in 11 chlldren 24-hour secretion was normal. The GHRH test does not therefore make it posslble to differentlate in testing for pituitary deflclcncy and cannot be considered as a diagnotic test for GH deficiency. tively 2) the diagnosis of growth hormone deficiency may be more difficult to establish in patients with isolated growth hormone deficiency. 
Switzerland. NYCTIIEMEIUXL GH SECRETION IN RESPONSE TO IV CONTINUOUS
Basal plasma GlI releasing hormone (GHRH) concentrations were measured after extraction by RIA in 240 healthy normal subjects between birth and 80 years of age: 32 full term newborns (cord blood) 53 prepubertal children of at least 6 years of age, 155 pubertal children at Tanner's stage I1 to V, 8 male adults, 20 old subjects of at least 70 years of age. Basal plasma GIIRH was found to be respectively mean * SEM 62 f 4 pg/ml in newborns, 40 ! L 4 pg/ml in prepubertal children, 66 f 5 pg/ml at stage I1 of puberty, 123 f 17 pg/ml at stage 111, 136 k 22 pg/n~l at stage IV and 60 f 5 pg/ml at stage V, 29 f 4 pg/ml in adults and 20 f 5 pg/ml in old people. This study indicates an increase in GHRH basal levels throughout puberty, stage of life where GI3 secretion is increased, and a progressive decrease with adult and old age, stage of life where GI3 secretion is lower.
PERFUSION, BOLUS INJECTIONS OR SUBCUTANEOUS ADMINIS-
As a preliminary step to the potential use of growth hormone releasing factor (GRF) in pituitary dwarfism, growth hormone (GH) response to the 1-29 fragment of the GPF molecule (given by AresSerono) was studied in 6 normal male volunteers (ape 19-23yrs). According to a pre-determined dose-response curve, an iv continuous perfusion (O.lug/kg/hr) and bolus injections (0.3ug/kg/3hr) i.e. a total dose of 2.4ug/kp, were given over 24 hours in each subject at a week interval. Furthermore, GRF was also injected subcutaneously at Opm (1.0 or 5.0ug/kg). Plasma Gli levels were measured at 20' interval and the results compared to a control period. Food intake and sleep periods were recorded. Continuous GRF perfusion produced an increase in GI1 pulses (7.05.1 vs 4.1 +1.0 peaks/day, pq0.001) as well as a constant but not signifi--cant rise in peak amplitude. Bolus injections caused GH release in 44/48 injections. This release was particularly marked during night time. Given subcutaneously, GRF caused a moderate rise in GI< in 3/4 subjccts, using the highest dosage only. In conclusion, GRF(1-29NH2) is effective in increasing Gli secretion in normal males without apparent desensltizatlon of the pituitary and with maximal sensitivity and response during night time.
